Quantcast

Latest glioblastoma multiforme Stories

2014-09-30 08:32:11

SAN ANTONIO, Sept. 30, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be presenting at the upcoming 2nd Global Life Sciences Conference on October 2, 2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange. The conference is sponsored by WedBush Europe and WDM Capital. Some of the Central and Eastern European leading life science...

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 08:32:13

SYDNEY, Sept. 29, 2014 /PRNewswire/ -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV that was broadcast on Saturday September 27th during the national 7.00 pm news bulletin and on the following day on Weekend Breakfast. The interview concerned the Company's efforts in bringing its drug candidate, Trilexium, into the clinic in Australia for the treatment of primary brain cancers such as glioblastoma multiforme. The...

2014-09-29 08:29:30

Follows CytRx's Strategy to Develop a Global Oncology Franchise in Numerous Orphan Indications LOS ANGELES, Sept. 29, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung...

2014-09-25 08:26:59

Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals of 20.0 and 8.5 months, respectively ST. HELIER, Jersey, Sept. 25, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that survival and efficacy data from its U.S. patient registry will be presented at the European Society for Medical Oncology (ESMO) Meeting...

2014-09-22 08:28:11

Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from several clinical studies evaluating potential new medicines in the company's oncology pipeline will be presented at the upcoming 2014 European Society of Medical Oncology (ESMO) Annual Congress, September 26-30, in Madrid, Spain. Data being presented include results...

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-15 08:29:14

BETHESDA, Md., Sept. 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, CEO, will present at SMi's 3rd Annual Cancer Vaccines Conference being held in Central London on September 15-16, 2014. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO Ms. Powers' presentation will provide updates about the Company's...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related